Will Ipilimumab be reimbursed by medical insurance?

Ipilimumab (Ipilimumab) is an immune checkpoint inhibitor used to treat some malignant tumors. Ipilimumab is approved to treat advanced or metastatic malignant melanoma, one of the most aggressive types of skin cancer. For these patients, ipilimumab is often combined with other antineoplastic drugs to improve survival and disease control. Ipilimumab may also be used to treat certain types of colorectal cancer, particularly those that have metastasized and have spread to other sites. In this case, ipilimumab is often used in combination with chemotherapy drugs.

Ipilimumab is not currently on the market in China, and even less reimbursed by medical insurance. Therefore, patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug costs about 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.

In addition to the above indications, ipilimumab is also being studied in clinical studies in a number of other cancer types to explore its potential efficacy. This includes lung cancer, pancreatic cancer, prostate cancer, and more. However, these applications are often experimental and more research is needed to determine their safety and effectiveness.

It is worth noting that ipilimumab is a type of immunotherapy, and its mechanism of action involves lifting the immune system's suppression of cancer cells, thereby enhancing the autoimmune response. However, this can also lead to immune-related side effects, such as skin reactions, gastrointestinal problems, and immune disorders. Therefore, when using ipilimumab, medical professionals need to monitor patients closely and take necessary steps to manage potential side effects.

xa0